Scholarlink

Background <p>Laminin alpha-5 (LAMA5), a major extracellular matrix component, is involved in tumor progression by modulating cell adhesion, migration, and tissue architecture. However, its specific role in breast cancer (BRCA) remains unclear.</p> Methods <p>We analyzed LAMA5 expression in BRCA and normal tissues using TCGA and GTEx datasets. Differential expression analysis was conducted using DESeq2. Survival associations were assessed using Kaplan–Meier and Cox regression models. GSEA was performed to identify LAMA5-related biological pathways. Immune infiltration was evaluated using CIBERSORT and ESTIMATE algorithms. Single-cell RNA sequencing and spatial transcriptomics were used to explore the spatial distribution and cellular localization of LAMA5. Drug sensitivity and immunotherapy response analyses were also conducted.</p> Results <p>LAMA5 was significantly downregulated in BRCA tissues compared to normal tissues. Higher LAMA5 expression was associated with better recurrence-free and overall survival. Functional enrichment analysis revealed that LAMA5 is involved in immune regulation and extracellular matrix-related pathways. Single-cell RNA sequencing and spatial transcriptomics demonstrated spatial and cellular heterogeneity of LAMA5 expression in BRCA. Immune-related analyses suggested that LAMA5 may influence immune cell infiltration and contribute to immune microenvironment remodeling. ROC analysis indicated moderate predictive value for immunotherapy response (AUC = 0.704), and LAMA5 expression was positively associated with sensitivity to chemotherapeutic agents including cisplatin and docetaxel.</p> Conclusion <p>LAMA5 is a potential prognostic biomarker in BRCA and may play a dual role in modulating tumor progression and immune responses. Its association with drug sensitivity and immunotherapy outcomes highlights its value as a potential therapeutic target in precision oncology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The role of LAMA5 in breast cancer progression and its potential in immunotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月22日

查看全文
  • Xiaoli Zhang,
  • Hongfang Yan,
  • Lihan Bie,
  • Zheng Xu,
  • Xiaoyang Yao,
  • Zhilan Li,
  • Chengshan He,
  • Zhouhong Xiang,
  • Xiudi Jiang

摘要

Background

Laminin alpha-5 (LAMA5), a major extracellular matrix component, is involved in tumor progression by modulating cell adhesion, migration, and tissue architecture. However, its specific role in breast cancer (BRCA) remains unclear.

Methods

We analyzed LAMA5 expression in BRCA and normal tissues using TCGA and GTEx datasets. Differential expression analysis was conducted using DESeq2. Survival associations were assessed using Kaplan–Meier and Cox regression models. GSEA was performed to identify LAMA5-related biological pathways. Immune infiltration was evaluated using CIBERSORT and ESTIMATE algorithms. Single-cell RNA sequencing and spatial transcriptomics were used to explore the spatial distribution and cellular localization of LAMA5. Drug sensitivity and immunotherapy response analyses were also conducted.

Results

LAMA5 was significantly downregulated in BRCA tissues compared to normal tissues. Higher LAMA5 expression was associated with better recurrence-free and overall survival. Functional enrichment analysis revealed that LAMA5 is involved in immune regulation and extracellular matrix-related pathways. Single-cell RNA sequencing and spatial transcriptomics demonstrated spatial and cellular heterogeneity of LAMA5 expression in BRCA. Immune-related analyses suggested that LAMA5 may influence immune cell infiltration and contribute to immune microenvironment remodeling. ROC analysis indicated moderate predictive value for immunotherapy response (AUC = 0.704), and LAMA5 expression was positively associated with sensitivity to chemotherapeutic agents including cisplatin and docetaxel.

Conclusion

LAMA5 is a potential prognostic biomarker in BRCA and may play a dual role in modulating tumor progression and immune responses. Its association with drug sensitivity and immunotherapy outcomes highlights its value as a potential therapeutic target in precision oncology.